The nation of Zimbabwe has declined a major American healthcare agreement worth 367 million US dollars (£272m) spanning five years due to Washington's demand for confidential biological samples.
The decision was revealed after a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government representative later explained that the United States was seeking genetic material for scientific study and commercial gain while was not willing to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further negotiations to find a agreement agreeable to all parties so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection follows a similar situation in Kenya, where a court suspended a similar deal with the US following concerns were filed about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
According to statements, Sixteen African countries have so far agreed to similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"In essence, our nation would supply the raw materials for medical research with no assurance that the final treatments would be accessible to our people should a new pandemic emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures previously set up through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage future pandemics.
"This framework is designed to ensure that when a nation contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation might be structured in a manner that honours the independence and interests of each country."
Health Experts Response
A leading public health body said it understood the government's concerns, but urged that negotiations need to persist considering much of the country's Aids initiatives depended on international support.
"Where specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
The halted deal emphasises the complex debate between accepting vital international aid and protecting a country's data in an increasingly interconnected world.